In B-ALL cells, we employed CRISPR-Cas9 to achieve double KO of HDAC1/HDAC2 and validated the deacetylation activities of HDAC1/2 on H3K27ac (Figure S5D). This evidence concerns the gene HDAC2 and acute lymphoblastic leukemia.